Advanced Autoantibody Testing in Systemic Sclerosis

Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication. Clinicians have been limited to antinuclear antibody (ANA), anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Almaabdi, Kholoud, Ahmad, Zareen, Johnson, Sindhu R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001109/
https://www.ncbi.nlm.nih.gov/pubmed/36899995
http://dx.doi.org/10.3390/diagnostics13050851
_version_ 1784904053234335744
author Almaabdi, Kholoud
Ahmad, Zareen
Johnson, Sindhu R.
author_facet Almaabdi, Kholoud
Ahmad, Zareen
Johnson, Sindhu R.
author_sort Almaabdi, Kholoud
collection PubMed
description Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication. Clinicians have been limited to antinuclear antibody (ANA), antitopoisomerase I (also known as anti-Scl-70) antibody, and anticentromere antibody testing. Many clinicians now have improved access to an expanded profile of autoantibody testing. In this narrative review article, we review the epidemiology, clinical associations, and prognostic value of advanced autoantibody testing in people with systemic sclerosis.
format Online
Article
Text
id pubmed-10001109
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-100011092023-03-11 Advanced Autoantibody Testing in Systemic Sclerosis Almaabdi, Kholoud Ahmad, Zareen Johnson, Sindhu R. Diagnostics (Basel) Review Systemic sclerosis is a systemic autoimmune rheumatic disease characterized by immune abnormalities, leading to vasculopathy and fibrosis. Autoantibody testing has become an increasingly important part of diagnosis and prognostication. Clinicians have been limited to antinuclear antibody (ANA), antitopoisomerase I (also known as anti-Scl-70) antibody, and anticentromere antibody testing. Many clinicians now have improved access to an expanded profile of autoantibody testing. In this narrative review article, we review the epidemiology, clinical associations, and prognostic value of advanced autoantibody testing in people with systemic sclerosis. MDPI 2023-02-23 /pmc/articles/PMC10001109/ /pubmed/36899995 http://dx.doi.org/10.3390/diagnostics13050851 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Almaabdi, Kholoud
Ahmad, Zareen
Johnson, Sindhu R.
Advanced Autoantibody Testing in Systemic Sclerosis
title Advanced Autoantibody Testing in Systemic Sclerosis
title_full Advanced Autoantibody Testing in Systemic Sclerosis
title_fullStr Advanced Autoantibody Testing in Systemic Sclerosis
title_full_unstemmed Advanced Autoantibody Testing in Systemic Sclerosis
title_short Advanced Autoantibody Testing in Systemic Sclerosis
title_sort advanced autoantibody testing in systemic sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10001109/
https://www.ncbi.nlm.nih.gov/pubmed/36899995
http://dx.doi.org/10.3390/diagnostics13050851
work_keys_str_mv AT almaabdikholoud advancedautoantibodytestinginsystemicsclerosis
AT ahmadzareen advancedautoantibodytestinginsystemicsclerosis
AT johnsonsindhur advancedautoantibodytestinginsystemicsclerosis

Ejemplares similares